Qol Holdings Co., Ltd. (3034.T)
- Previous Close
2,218.00 - Open
2,203.00 - Bid 2,220.00 x --
- Ask 2,224.00 x --
- Day's Range
2,201.00 - 2,268.00 - 52 Week Range
1,187.00 - 2,395.00 - Volume
230,200 - Avg. Volume
276,327 - Market Cap (intraday)
83.32B - Beta (5Y Monthly) --
- PE Ratio (TTM)
19.68 - EPS (TTM)
112.83 - Earnings Date Jul 31, 2025 - Aug 4, 2025
- Forward Dividend & Yield 34.00 (1.53%)
- Ex-Dividend Date Sep 29, 2025
- 1y Target Est
2,900.00
Qol Holdings Co., Ltd., together with its subsidiaries, engages in management of dispensing pharmacies and business process outsourcing contracting businesses in Japan. The company operates dispensing pharmacies through one-on-one store opening based on one-on-one trust relationships with medical institutions. It also undertakes sales and marketing research activities for pharmaceutical companies; and provides temporary staff dispatch for pharmacists, nurses, registered sellers, registered dietitians, etc. In addition, the company offers clinical trial support services for pharmaceuticals and food products; support, monitoring, and technician dispatch services of managers for various processes, from planning of trial execution plans to monitoring, secretariat support, statistical analysis, and the presentation of conference papers; and publishes books and magazines for medical professionals and patients. The company was formerly known as Qol Co., Ltd. and changed its name to Qol Holdings Co., Ltd. in October 2018. Qol Holdings Co., Ltd. was founded in 1992 and is headquartered in Tokyo, Japan.
www.qolhd.co.jp--
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: 3034.T
View MorePerformance Overview: 3034.T
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 3034.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 3034.T
View MoreValuation Measures
Market Cap
83.32B
Enterprise Value
88.65B
Trailing P/E
19.70
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.38
Price/Book (mrq)
1.55
Enterprise Value/Revenue
0.41
Enterprise Value/EBITDA
5.23
Financial Highlights
Profitability and Income Statement
Profit Margin
1.96%
Return on Assets (ttm)
6.07%
Return on Equity (ttm)
13.01%
Revenue (ttm)
263.97B
Net Income Avi to Common (ttm)
5.16B
Diluted EPS (ttm)
112.83
Balance Sheet and Cash Flow
Total Cash (mrq)
26.73B
Total Debt/Equity (mrq)
66.10%
Levered Free Cash Flow (ttm)
--